Table 5.
Univariate Analysis of OS and PFS
| OS | PFS | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TARE_alone (n=55) | TARE_sorafenib (n=74) | TARE_alone (n=55) | TARE_sorafenib (n=74) | |||||||||||||
| n | C, n | Median (95% CI), months | p-value | n | C, n | Median (95% CI), months | p-value | n | C, n | Median (95% CI), months | p-value | n | C, n | Median (95% CI), months | p-value | |
| Sex | ||||||||||||||||
| Male | 42 | 27 | 35.2 (0–76.3) | 0.468 | 58 | 20 | 12.4 (8.7–16.1) | 0.400 | 42 | 16 | 9.1 (7.0–11.2) | 0.479 | 58 | 7 | 6.7 (3.6–9.8) | 0.002 |
| Female | 13 | 7 | 19.1 (10.9–27.2) | 16 | 5 | 14.4 (5.9–23.0) | 13 | 4 | 6.8 (1.7–12.0) | 16 | 0 | 2.8 (1.9–3.7) | ||||
| Ethnicitya | ||||||||||||||||
| Hispanic | 5 | 3 | NA | 0.478 | 9 | 4 | 11.5 (3.9–19.1) | 0.096 | 5 | 1 | NA | 0.769 | 9 | 1 | 3.1 (2.1–4.0) | 0.087 |
| Black | 3 | 1 | NA | 9 | 2 | 7.1 (4.4–9.8) | 3 | 1 | NA | 9 | 1 | 3.9 (2.7–5.1) | ||||
| Asian | 1 | 1 | NA | 10 | 4 | 11.3 (8.6–14.1) | 1 | 1 | NA | 10 | 1 | 4.9 (2.1–7.7) | ||||
| Non-Hispanic white | 46 | 29 | NA | 46 | 15 | 14.8 (10.6–18.9) | 46 | 17 | NA | 46 | 4 | 7.1 (3.2–10.9) | ||||
| Age, years | ||||||||||||||||
| <65 | 15 | 7 | 21.6 (7.3–36.0) | 0.754 | 43 | 12 | 11.6 (5.8–17.4) | 0.391 | 15 | 4 | 5.6 (3.2–7.9) | 0.783 | 43 | 5 | 4.6 (3.0–6.2) | 0.656 |
| ≥65 | 40 | 26 | 35.2 (8.6–61.9) | 31 | 13 | 14.4 (10.6–18.2) | 40 | 16 | 9.1 (7.2–11.0) | 31 | 2 | 6.3 (2.8–9.9) | ||||
| Tumor gradeb | ||||||||||||||||
| Well differentiated | 13 | 10 | NA | 0.475 | 19 | 5 | 14.4 (11.3–17.5) | 0.972 | 13 | 6 | 12.3 (0–26.4) | 0.110 | 19 | 2 | 7.7 (1.6–13.8) | 0.805 |
| Moderately differentiated | 17 | 10 | 21.6 (6.7–36.5) | 25 | 9 | 11.6 (4.7–18.5) | 17 | 4 | 6.8 (0.5–13.2) | 25 | 2 | 5.8 (1.8–9.8) | ||||
| Poorly differentiated | 3 | 1 | 9.3 (2.0–16.7) | 10 | 3 | 10.3 (0–41.7) | 3 | 0 | 2.2 (0.4–4.1) | 10 | 1 | 3.0 (0–9.1) | ||||
| ECOG performance statusc | ||||||||||||||||
| 0 | 27 | 17 | 35.2 (12.3–58.2) | 0.050 | 38 | 12 | 11.3 (6.2–16.5) | 0.421 | 27 | 11 | 12.2 (9.9–14.4) | 0.038 | 38 | 3 | 4.6 (2.2–7.0) | 0.155 |
| 1 | 25 | 12 | 14.4 (5.8–23.0) | 34 | 12 | 14.5 (0–29.6) | 25 | 8 | 4.7 (2.8–6.5) | 34 | 4 | 7.7 (2.6–12.8) | ||||
| BCLC staged | ||||||||||||||||
| B | 22 | 12 | 35.2 (5.1–65.3) | 0.155 | 16 | 4 | 11.3 (7.3–15.3) | 0.337 | 22 | 8 | 12.2 (7.1–17.2) | 0.062 | 16 | 0 | 5.7 (3.9–7.4) | 0.490 |
| C | 27 | 15 | 14.4 (1.4–27.3) | 58 | 21 | 14.5 (9.8–19.1) | 27 | 8 | 4.7 (2.7–6.6) | 58 | 7 | 4.9 (2.2–7.6) | ||||
| Cirrhosis | ||||||||||||||||
| Absence | 13 | 6 | 19.1 (4.1–34.0) | 0.856 | 27 | 8 | 14.4 (9.7–19.2) | 0.564 | 13 | 1 | 5.6 (0–11.8) | 0.178 | 27 | 2 | 4.9 (2.9–6.9) | 0.738 |
| Presence | 42 | 27 | 27.4 (8.9–46.0) | 47 | 17 | 12.3 (6.1–18.5) | 42 | 19 | 10.6 (4.5–16.8) | 47 | 5 | 5.7 (1.9–9.4) | ||||
| MVI | ||||||||||||||||
| Absence | — | — | — | — | 48 | 14 | 11.5 (8.0–15.1) | 0.249 | — | — | — | — | 48 | 4 | 4.9 (2.2–7.5) | 0.181 |
| Presence | — | — | — | 26 | 11 | 18.4 (10.6–26.2) | — | — | — | 26 | 3 | 5.1 (0–10.9) | ||||
| EHD | ||||||||||||||||
| Absence | — | — | — | — | 55 | 21 | 14.4 (10.1–18.9) | 0.188 | — | — | — | — | 55 | 5 | 5.8 (2.6–9.0) | 0.245 |
| Presence | — | — | — | 19 | 4 | 9.4 (9.0–9.8) | — | — | — | 19 | 2 | 2.8 (1.2–4.4) | ||||
| Number of tumors | ||||||||||||||||
| Single | 10 | 8 | NA | 0.354 | 9 | 4 | 15.9 (11.0–20.9) | 0.865 | 10 | 5 | 10.7 (4.4–16.9) | 0.264 | 9 | 3 | 14.4 (9.2–19.7) | 0.129 |
| Multiple | 45 | 25 | 21.6 (8.9–34.4) | 65 | 21 | 12.3 (7.6–17.0) | 45 | 15 | 6.8 (2.2–11.5) | 65 | 4 | 4.9 (2.9–6.8) | ||||
| Lobar involvement | ||||||||||||||||
| Unilobar | 32 | 23 | 27.4 (4.2–50.7) | 0.025 | 20 | 10 | 15.9 (8.5–23.4) | 0.700 | 32 | 15 | 12.3 (6.5–18.0) | 0.038 | 20 | 5 | 10.5 (2.1–18.8) | 0.374 |
| Bilobar | 23 | 10 | 10.2 (8.0–12.4) | 54 | 15 | 12.3 (7.6–17.0) | 23 | 5 | 4.7 (2.5–6.8) | 54 | 2 | 4.9 (2.8–6.9) | ||||
| Intrahepatic tumor | ||||||||||||||||
| ≤50% | — | — | — | — | 34 | 16 | 21.6 (6.6–36.6) | 0.024 | — | — | — | — | 34 | 4 | 5.7 (0.7–10.7) | 0.510 |
| >50% | — | — | — | 40 | 9 | 11.3 (8.1–14.5) | — | — | — | 40 | 3 | 4.9 (2.6–7.2) | ||||
| AFP | ||||||||||||||||
| <400 | 45 | 29 | 35.2 (15.3–55.1) | <0.001 | 47 | 17 | 14.8 (9.6–19.9) | 0.091 | 45 | 18 | 10.2 (8.0–12.4) | 0.005 | 47 | 5 | 6.3 (3.4–9.3) | 0.053 |
| ≥400 | 10 | 4 | 5.0 (2.6–7.3) | 27 | 8 | 9.4 (7.0–11.9) | 10 | 2 | 2.2 (0.3–4.1) | 27 | 2 | 3.5 (2.5–4.5) | ||||
| Child–Pugh class | ||||||||||||||||
| A | 50 | 32 | 21.6 (7.0–36.3) | 0.261 | 71 | 24 | 12.4 (9.2–15.5) | 0.669 | 50 | 19 | 9.1 (6.9–11.3) | 0.153 | 71 | 7 | 5.1 (2.5–7.7) | 0.061 |
| B | 5 | 1 | 8.6 (0–21.0) | 3 | 1 | 41.0 (NA) | 5 | 1 | 2.2 (0.4–4.0) | 3 | 0 | 2.7 (0.3–5.2) | ||||
Notes: aNo statistics computed because all cases were censored in one stratum (Asian). bExcluded patients without biopsy: TARE_alone (n=22) and TARE_sorafenib (n=20). cExcluded patients with ECOG ≥2: TARE_alone, ECOG 2 (n=2) and ECOG 3 (n=1); TARE_sorafenib, ECOG 2 (n=2). dExcluded patients with BCLC A (n=5) and BCLC D (n=1) in TARE_alone subgroup.
Abbreviations: C, censored; NA, not available.